Home › Companies › Avidity Biosciences, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Avidity Biosciences, Inc.’s Form 8-K, filed 2026-02-26 (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore Avidity Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Avidity Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-02-26 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Proposal 1: The Transactions Proposal To adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the " Merger Agreement "), among Novartis AG, a company limited by shares ( Aktiengesellschaft ) incorporated under the laws of Switzerland (" No | 123,351,048 | 8,090 | 60,331 | -- | 296,100 | Majority: yes |
| Proposal 3: The Non-Binding Merger-Related Compensation Proposal To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to the Company's named executive officers in connection with the transactions contemplated by the | 101,383,553 | 21,654,186 | 381,730 | -- | 296,100 | Majority: yes |
Source: Avidity Biosciences, Inc., Form 8-K, filed with the SEC on 2026-02-26 — read the filing on EDGAR.
Each item below shows how the 283 asset managers that disclosed a Avidity Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Avidity Biosciences, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2026-02-26.
Combines 6 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Avidity Biosciences, Inc.’s own tally for this item (“Proposal 3: The Non-Binding Merger-Related Compensation Proposal To approve, on a non-binding, advisory basis, the compensation that may be paid or become payable to the Company's named executive officers in connection w”): 101,383,553 for, 21,654,186 against, per its Form 8-K filed 2026-02-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 151,205,000 outstanding shares: 67% for, 14% against (81% of the company cast a for/against vote).
The 270 asset managers below cast 82% of the shares they voted on this item FOR (99,579,314 for, 21,992,105 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 13,535,371 | 1,051 | 0 | 0 | For |
| BlackRock | 3,184,266 | 9,438,494 | 0 | 0 | Against |
| Janus Henderson | 11,363,308 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 8,641,031 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 8,515,749 | 0 | 0 | 0 | For |
| OAK RIDGE INVESTMENTS LLC | 5,696,982 | 0 | 0 | 0 | For |
| Pentwater Capital Management LP | 5,696,982 | 0 | 0 | 0 | For |
| Fidelity | 3,135,238 | 2,348,166 | 0 | 0 | For |
| BALYASNY ASSET MANAGEMENT L.P. | 0 | 4,491,544 | 0 | 0 | Against |
| State Street | 3,797,871 | 6,000 | 0 | 0 | For |
| Fiera Capital Corp | 3,521,471 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 3,233,000 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,135,141 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,502,419 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,396,003 | 0 | 0 | 0 | For |
| Charles Schwab | 2,366,665 | 489 | 0 | 0 | For |
| GLAZER CAPITAL, LLC | 2,039,716 | 0 | 0 | 0 | For |
| TIG Advisors, LLC | 1,452,833 | 0 | 0 | 0 | For |
| Weiss Asset Management LP | 1,079,838 | 0 | 0 | 0 | For |
| Northern Trust | 998,899 | 0 | 0 | 0 | For |
| MERGER FUND | 978,849 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 0 | 890,580 | 0 | 0 | Against |
| Goldman Sachs | 861,259 | 0 | 0 | 0 | For |
| AllianceBernstein | 0 | 800,016 | 0 | 0 | Against |
| Gabelli | 637,396 | 0 | 0 | 0 | For |
Showing the 25 largest of 270 asset managers. See all 270 in the interactive database.
Meeting held 2026-02-26.
Combines 4 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Avidity Biosciences, Inc.’s own tally for this item (“Proposal 1: The Transactions Proposal To adopt (i) the Agreement and Plan of Merger, dated as of October 25, 2025 (the " Merger Agreement "), among Novartis AG, a company limited by shares ( Aktiengesellschaft ) incorpor”): 123,351,048 for, 8,090 against, per its Form 8-K filed 2026-02-26 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 151,205,000 outstanding shares: 82% for, 0.1% against (82% of the company cast a for/against vote).
The 67 asset managers below cast 100% of the shares they voted on this item FOR (32,565,486 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,406,458 | 0 | 0 | 0 | For |
| BlackRock | 7,185,431 | 0 | 0 | 0 | For |
| Fidelity | 2,956,705 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,396,003 | 0 | 0 | 0 | For |
| State Street | 1,500,037 | 0 | 0 | 0 | For |
| Charles Schwab | 1,179,880 | 0 | 0 | 0 | For |
| MERGER FUND | 978,849 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 890,580 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 531,219 | 0 | 0 | 0 | For |
| Equitable | 263,025 | 0 | 0 | 0 | For |
| TIAA | 238,916 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,491 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 142,238 | 0 | 0 | 0 | For |
| Jackson National | 136,623 | 0 | 0 | 0 | For |
| Lincoln Financial | 105,418 | 0 | 0 | 0 | For |
| Tidal Trust II | 105,336 | 0 | 0 | 0 | For |
| GMO | 90,328 | 0 | 0 | 0 | For |
| Global X | 79,484 | 0 | 0 | 0 | For |
| DWS | 71,673 | 0 | 0 | 0 | For |
| ProShares | 64,797 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 64,705 | 0 | 0 | 0 | For |
| New York Life | 59,918 | 0 | 0 | 0 | For |
| Northern Trust | 58,060 | 0 | 0 | 0 | For |
| John Hancock | 56,782 | 0 | 0 | 0 | For |
| Dunham Funds | 56,181 | 0 | 0 | 0 | For |
Showing the 25 largest of 67 asset managers. See all 67 in the interactive database.
Meeting held 2026-02-26.
95% fund support · no official result
The 66 asset managers below cast 95% of the shares they voted on this item FOR (30,921,141 for, 1,635,907 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,406,458 | 0 | 0 | 0 | For |
| BlackRock | 7,185,431 | 0 | 0 | 0 | For |
| Fidelity | 2,956,705 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 2,396,003 | 0 | 0 | 0 | For |
| State Street | 3,699 | 1,496,338 | 0 | 0 | Against |
| Charles Schwab | 1,179,880 | 0 | 0 | 0 | For |
| MERGER FUND | 978,849 | 0 | 0 | 0 | For |
| NEXPOINT FUNDS I | 890,580 | 0 | 0 | 0 | For |
| MUTUAL FUND SERIES TRUST | 531,219 | 0 | 0 | 0 | For |
| Equitable | 263,025 | 0 | 0 | 0 | For |
| TIAA | 238,916 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 190,491 | 0 | 0 | 0 | For |
| ARBITRAGE FUNDS | 142,238 | 0 | 0 | 0 | For |
| Jackson National | 136,623 | 0 | 0 | 0 | For |
| Lincoln Financial | 26,118 | 79,300 | 0 | 0 | Against |
| Tidal Trust II | 105,336 | 0 | 0 | 0 | For |
| GMO | 90,328 | 0 | 0 | 0 | For |
| Global X | 79,484 | 0 | 0 | 0 | For |
| DWS | 71,673 | 0 | 0 | 0 | For |
| ProShares | 64,797 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 64,705 | 0 | 0 | 0 | For |
| New York Life | 59,918 | 0 | 0 | 0 | For |
| Northern Trust | 58,060 | 0 | 0 | 0 | For |
| John Hancock | 56,782 | 0 | 0 | 0 | For |
| Dunham Funds | 56,181 | 0 | 0 | 0 | For |
Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.
Reported under meeting date 2026-02-23; no official results on file for that date.
99.8% fund support · no official result
The 7 asset managers below cast 99.8% of the shares they voted on this item FOR (1,061,500 for, 1,604 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Slotnik Capital, LLC | 735,000 | 0 | 0 | 0 | For |
| HARVEST MANAGEMENT LLC | 326,500 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 678 | 0 | 0 | Against |
| L2 Asset Management, LLC | 0 | 678 | 0 | 0 | Against |
| Ethic Inc. | 0 | 248 | 0 | 0 | Against |
| BOFA SECURITIES, INC. | 0 | 0 | 0 | 0 | -- |
| MERRILL LYNCH INTERNATIONAL | 0 | 0 | 0 | 0 | -- |
Meeting held 2026-02-26.
100% fund support · no official result
The 4 asset managers below cast 100% of the shares they voted on this item FOR (2,361,577 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| HBK INVESTMENTS L P | 2,294,654 | 0 | 0 | 0 | For |
| JPMorgan | 66,864 | 0 | 0 | 0 | For |
| Wilshire Advisors LLC | 40 | 0 | 0 | 0 | For |
| Coyle Financial Counsel LLC | 19 | 0 | 0 | 0 | For |
Ranked by the number of Avidity Biosciences, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 151,205,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 8.95% |
| 2 | BlackRock | 8.35% |
| 3 | Janus Henderson | 7.52% |
| 4 | RA CAPITAL MANAGEMENT, L.P. | 5.71% |
| 5 | Avoro Capital Advisors LLC | 5.63% |
| 6 | OAK RIDGE INVESTMENTS LLC | 3.77% |
| 7 | Pentwater Capital Management LP | 3.77% |
| 8 | Fidelity | 3.63% |
| 9 | BALYASNY ASSET MANAGEMENT L.P. | 2.97% |
| 10 | State Street | 2.52% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 9.03% | 13F |
| RTW Investments, LP | 7.99% | DEF14A |
| FMR LLC | 6.88% | DEF14A |
| BlackRock, Inc. | 5.98% | DEF14A |
| Avoro Capital Advisors LLC | 5.63% | 13G |
| JANUS HENDERSON GROUP PLC | 4.59% | 13G |
| RA Capital Management, L.P. | 4.17% | DEF14A |
| Sarah Boyce | 1.30% | DEF14A |
| Morgan Stanley | 0.72% | 13F |
| Wellington Management Group LLP | 0.48% | 13G |
Percentages above are of 151,205,000 shares outstanding, as reported by Avidity Biosciences, Inc. on its Form 10-K dated 2025-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Avidity Biosciences, Inc.’s 10-K dated 2025-12-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At Avidity Biosciences, Inc.'s shareholder meeting held 2026-02-26, in the 2025-2026 proxy season, 283 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,017 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation that may be paid or become… — FOR was 82% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Avidity Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-02-26.
Avidity Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).